Yet the clinical nuance behind incretin-based weight management prescribing is far more complex than public discourse suggests
So, read this below, here we highlight some case studies on GLP-1 agonists frequently exhibited negative effects
Nausea, vomiting, and other gastrointestinal symptoms are common, particularly when starting or increasing the dose and in T1D trials, these rates were similar to those seen in T2D and obesity trials
These capsules use BPC-157 Arginate Salt to enhance stability and bioavailability, ensuring efficient absorption in the digestive tract
A large cohort study of 461,382 GLP-1 users found that 12.7% of patients had a new nutritional deficiency diagnosis at just 6 months of therapy
The duration bars in the chart show the additional paid leave added on top of disability coverage, not the total leave period